91 related articles for article (PubMed ID: 14980595)
1. Solid phase synthesis of selective caspase-3 peptide inhibitors.
Grimm EL; Roy B; Aspiotis R; Bayly CI; Nicholson DW; Rasper DM; Renaud J; Roy S; Tam J; Tawa P; Vaillancourt JP; Xanthoudakis S; Zamboni RJ
Bioorg Med Chem; 2004 Mar; 12(5):845-51. PubMed ID: 14980595
[TBL] [Abstract][Full Text] [Related]
2. Using peptidic inhibitors to systematically probe the S1' site of caspase-3 and caspase-7.
Goode DR; Sharma AK; Hergenrother PJ
Org Lett; 2005 Aug; 7(16):3529-32. PubMed ID: 16048334
[TBL] [Abstract][Full Text] [Related]
3. Lipophilic versus hydrogen-bonding effect in P3 on potency and selectivity of valine aspartyl ketones as caspase 3 inhibitors.
Mellon C; Aspiotis R; Black CW; Bayly CI; Grimm EL; Giroux A; Han Y; Isabel E; McKay DJ; Nicholson DW; Rasper DM; Roy S; Tam J; Thornberry NA; Vaillancourt JP; Xanthoudakis S; Zamboni R
Bioorg Med Chem Lett; 2005 Sep; 15(17):3886-90. PubMed ID: 16023344
[TBL] [Abstract][Full Text] [Related]
4. Solid-phase synthesis of kojic acid-tripeptides and their tyrosinase inhibitory activity, storage stability, and toxicity.
Kim H; Choi J; Cho JK; Kim SY; Lee YS
Bioorg Med Chem Lett; 2004 Jun; 14(11):2843-6. PubMed ID: 15125944
[TBL] [Abstract][Full Text] [Related]
5. 1,3-Dioxo-4-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolines as potent caspase-3 inhibitors.
Kravchenko DV; Kysil VV; Ilyn AP; Tkachenko SE; Maliarchouk S; Okun IM; Ivachtchenko AV
Bioorg Med Chem Lett; 2005 Apr; 15(7):1841-5. PubMed ID: 15780618
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10.
Ekici OD; Li ZZ; Campbell AJ; James KE; Asgian JL; Mikolajczyk J; Salvesen GS; Ganesan R; Jelakovic S; Grütter MG; Powers JC
J Med Chem; 2006 Sep; 49(19):5728-49. PubMed ID: 16970398
[TBL] [Abstract][Full Text] [Related]
7. A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score.
Yoshimori A; Takasawa R; Tanuma S
BMC Pharmacol; 2004 May; 4():7. PubMed ID: 15154972
[TBL] [Abstract][Full Text] [Related]
8. Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.
Han Y; Giroux A; Colucci J; Bayly CI; Mckay DJ; Roy S; Xanthoudakis S; Vaillancourt J; Rasper DM; Tam J; Tawa P; Nicholson DW; Zamboni RJ
Bioorg Med Chem Lett; 2005 Feb; 15(4):1173-80. PubMed ID: 15686936
[TBL] [Abstract][Full Text] [Related]
9. In situ assembly of enzyme inhibitors using extended tethering.
Erlanson DA; Lam JW; Wiesmann C; Luong TN; Simmons RL; DeLano WL; Choong IC; Burdett MT; Flanagan WM; Lee D; Gordon EM; O'Brien T
Nat Biotechnol; 2003 Mar; 21(3):308-14. PubMed ID: 12563278
[TBL] [Abstract][Full Text] [Related]
10. Solution and solid-phase synthesis of potent inhibitors of hepatitis C virus NS3 proteinase.
Beevers R; Carr MG; Jones PS; Jordan S; Kay PB; Lazell RC; Raynham TM
Bioorg Med Chem Lett; 2002 Feb; 12(4):641-3. PubMed ID: 11844690
[TBL] [Abstract][Full Text] [Related]
11. Solid-phase syntheses of olefin-containing inhibitors for HTLV-1 protease using the Horner-Emmons reaction.
Bang JK; Naka H; Teruya K; Aimoto S; Konno H; Nosaka K; Tatsumi T; Akaji K
J Org Chem; 2005 Dec; 70(25):10596-9. PubMed ID: 16323881
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors.
Kravchenko DV; Kuzovkova YA; Kysil VM; Tkachenko SE; Maliarchouk S; Okun IM; Balakin KV; Ivachtchenko AV
J Med Chem; 2005 Jun; 48(11):3680-3. PubMed ID: 15916416
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8.
James KE; Asgian JL; Li ZZ; Ekici OD; Rubin JR; Mikolajczyk J; Salvesen GS; Powers JC
J Med Chem; 2004 Mar; 47(6):1553-74. PubMed ID: 14998341
[TBL] [Abstract][Full Text] [Related]
14. "Click" synthesis of small-molecule inhibitors targeting caspases.
Ng SL; Yang PY; Chen KY; Srinivasan R; Yao SQ
Org Biomol Chem; 2008 Mar; 6(5):844-7. PubMed ID: 18292873
[TBL] [Abstract][Full Text] [Related]
15. Pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors. Synthesis and SAR of 2-substituted 4-methyl-8-(morpholine-4-sulfonyl)-pyrrolo[3,4-c]quinoline-1,3-diones.
Kravchenko DV; Kysil VM; Tkachenko SE; Maliarchouk S; Okun IM; Ivachtchenko AV
Eur J Med Chem; 2005 Dec; 40(12):1377-83. PubMed ID: 16169127
[TBL] [Abstract][Full Text] [Related]
16. Correlating the fractional inhibition of caspase-3 in NT2 cells with apoptotic markers using an active-caspase-3 enzyme-linked immunosorbent assay.
Tawa P; Giroux A; Grimm E; Han Y; Nicholson DW; Xanthoudakis S
Anal Biochem; 2006 Mar; 350(1):32-40. PubMed ID: 16430849
[TBL] [Abstract][Full Text] [Related]
17. Solid phase combinatorial synthesis of benzothiazoles and evaluation of topoisomerase II inhibitory activity.
Choi SJ; Park HJ; Lee SK; Kim SW; Han G; Choo HY
Bioorg Med Chem; 2006 Feb; 14(4):1229-35. PubMed ID: 16242334
[TBL] [Abstract][Full Text] [Related]
18. Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors.
Ganesan R; Jelakovic S; Campbell AJ; Li ZZ; Asgian JL; Powers JC; Grütter MG
Biochemistry; 2006 Aug; 45(30):9059-67. PubMed ID: 16866351
[TBL] [Abstract][Full Text] [Related]
19. Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity.
Pereira NA; Song Z
Biochem Biophys Res Commun; 2008 Dec; 377(3):873-7. PubMed ID: 18976637
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1beta converting enzyme (ICE) inhibitors.
Soper DL; Sheville J; O'Neil SV; Wang Y; Laufersweiler MC; Oppong KA; Wos JA; Ellis CD; Fancher AN; Lu W; Suchanek MK; Wang RL; De B; Demuth TP
Bioorg Med Chem Lett; 2006 Aug; 16(16):4233-6. PubMed ID: 16782334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
